Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
62 participants
OBSERVATIONAL
2020-10-01
2021-10-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
They are expressed by vascular endothelium, immune cells (macrophages, neutrophils, and mast cells), uterus, placenta, cardiac muscle, liver, epithelium of the gastrointestinal tract, and many other tissues.
Although some galectins have intracellular functions, the majority of them have extracellular activities, which facilitate their contribution to cell adhesion, cell activation, and inflammation. Galectin-3 (Gal-3) is a unique pentamer of the galectins family and it is involved in both physiological functions; cell growth and differentiation, and pathological conditions; inflammation, fibrosis, and metastasis.
Regarding pregnancy, Gal-3 is proved to participate in angiogenesis, embryo developmental processes, and modulation of maternal immunity.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Serum Galectin-3 Levels in Placenta Accreta Spectrum Pregnancies
NCT05945446
Evaluation of the Role of Plasma Procalcitonin in Prediction of Intra-amniotic Infection in Preterm Premature Rupture of Membrane
NCT02104791
Plasma Concentration of Biological Markers in Placenta Accreta Spectrum
NCT04525534
Relationship Between Maternal Soluble Trigger Receptor Expressed on Myeloid Cells-1 (sTREM-1) and Placenta Accreta Spectrum
NCT05376410
Placental Growth Factor as a Predictor of Adverse Pregnancy Outcomes in Preeclamptic Women
NCT04374604
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CROSSOVER
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Normal pregnancy group
Galectin-3
Measurement of Gal-3 in Serum which will be isolated from the blood samples by ELISA (Enzyme-Linked immunosorbent Assay) (R\&D Systems, Minneapolis, MN, USA).
Placental Galactin-3
Measurement of Gal-3 in Villous and decidual tissues homogenate by ELISA
Placenta accreta at 24-32 weeks group
Galectin-3
Measurement of Gal-3 in Serum which will be isolated from the blood samples by ELISA (Enzyme-Linked immunosorbent Assay) (R\&D Systems, Minneapolis, MN, USA).
Placental Galactin-3
Measurement of Gal-3 in Villous and decidual tissues homogenate by ELISA
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Galectin-3
Measurement of Gal-3 in Serum which will be isolated from the blood samples by ELISA (Enzyme-Linked immunosorbent Assay) (R\&D Systems, Minneapolis, MN, USA).
Placental Galactin-3
Measurement of Gal-3 in Villous and decidual tissues homogenate by ELISA
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Age between 20-40 years.
3. Singleton pregnancy.
4. Women with suspicion of placenta accreta
5. Cases with mild vaginal bleeding or not having any vaginal bleeding.
Exclusion Criteria
2. Patients with known bleeding disorders or on anticoagulant therapy.
3. Patients refuse to participate.
20 Years
40 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Assiut University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Mohammed Khairy Ali
Assistant professor
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Women Health Hospital - Assiut university
Asyut, , Egypt
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
G-PA
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.